Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Using e-cigarettes to help smokers with serious mental illness reduce smoking

Official title: Effectiveness and Impact of Counseling Enhanced Using Electronic Cigarettes for Harm Reduction in People With Serious Mental Illness

Run by NYU Langone Health · NCT05815199 · Data updated 2026-11-12

This study is testing if e-cigarettes can help people with serious mental illness cut down on smoking compared to traditional nicotine replacement therapies.

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment60 (estimated)
SponsorNYU Langone Health
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedNovember 13, 2023
Main results expectedMarch 2027
Study endsMarch 2027
Registry record updatedSeptember 29, 2026
Trial IDNCT05815199 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 21 and older who smoke at least five combustible cigarettes per day and have a diagnosis of serious mental illness.

Probably not a fit

Patients who are currently attempting to quit smoking or have used other forms of tobacco in the past two weeks may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, randomized controlled trial aims to evaluate the effectiveness of e-cigarettes compared to nicotine replacement therapy in reducing combustible cigarette smoking among individuals diagnosed with serious mental illness. Participants will receive harm-reduction counseling and Ecological Momentary Intervention text messaging to support their smoking reduction efforts. The study will involve individuals who smoke at least five cigarettes per day and are interested in reducing their smoking without necessarily quitting completely. The trial will assess the impact of these interventions on smoking behavior over a specified period.

Why it matters

Potential benefit: If successful, this approach could provide a viable harm reduction strategy for smokers with serious mental illness, potentially leading to improved health outcomes.

How similar studies have gone: Other studies have explored harm reduction strategies for smoking, but the specific use of e-cigarettes in this population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Currently smokes 5 or more CPD
* Willingness and ability to provide informed consent
* Age of at least 21 years
* Has SMI diagnosis (such as Schizophrenia, Schizoaffective disorders, Bipolar disorder, Depressive disorders, Trauma and stressor related disorders etc.) as determined using the MINI tool
* Interested in reducing CC smoking but not necessarily trying to quit
* Own a mobile phone or have regular access to a mobile phone
* Able to provide an additional contact to improve follow-up rates

Exclusion Criteria:

* Is pregnant or breastfeeding
* Used tobacco other than CC in the past 2 weeks (e.g., EC, cigarillo)
* Currently engaged in an attempt to quit CC
* Change in dose of their psychotropic medication(s) in the last 30 days
* Meeting DSM-V criteria for current alcohol or substance use disorder except for nicotine use disorder and active mild alcohol or substance use disorders.
* Past month suicidal ideation/suicide attempt and/or psychiatric hospitalization in the last 30 days

Where it's running

  • NYU Langone Health
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.